Trial Profile
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2019 Results (N=221), a pooled analysis of four trials ((NCT01029054 , NCT01402284, NCT01816971 and NCT02405364) assessing clinical outcomes for Lenalidomide and dexamethasone (KRd) along with safety, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 30 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016 as per ClinicalTrials.gov record.
- 04 Jun 2012 Final results were published in the online version of Blood, and were reported in a media release.